Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study.

Inge van den Berg, Robert R J Coebergh van den Braak, Jeroen L A van Vugt, Jan N M Ijzermans, Stefan Buettner
Author Information
  1. Inge van den Berg: Department of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands. i.vandenBerg@erasmusmc.nl. ORCID
  2. Robert R J Coebergh van den Braak: Department of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands.
  3. Jeroen L A van Vugt: Department of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands.
  4. Jan N M Ijzermans: Department of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands.
  5. Stefan Buettner: Department of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands.

Abstract

BACKGROUND: Colorectal cancer is the third most common type of cancer in the world. We characterize a cohort of patients who survived up to 5 years without recurrence and identify factors predicting the probability of cure.
METHODS: We analyzed data of patients who underwent curative intent surgery for stage I-III CRC between 2007 and 2012 and who had had been included in a large multicenter study in the Netherlands. Cure was defined as 5-year survival without recurrence. Survival data were retrieved from a national registry.
RESULTS: Analysis of data of 754 patients revealed a cure rate of 65% (n = 490). Patients with stage I disease and T1- and N0-tumor had the highest probability of cure (94%, 95% and 90%, respectively). Those with a T4-tumor or N2-tumor had the lowest probability of cure (62% and 50%, respectively). A peak in the mortality rate for older patients early in follow-up suggests early excess mortality as an explanation. A similar trend was observed for stage III disease, poor tumor grade, postoperative complications, sarcopenia, and R1 resections. Patients with stage III disease, poor tumor grade, postoperative complications, sarcopenia, and R1 resections show a similar trend for decrease in CSS deaths over time.
CONCLUSION: In the studied cohort, the probability of cure for patients with stage I-III CRC ranged from 50 to 95%. Even though most patients will be cured from CRC with standard therapy, standard therapy is insufficient for those with poor prognostic factors, such as high T- and N-stage and poor differentiation grade.

References

  1. Epidemiol Health. 2018;40:e2018045 [PMID: 30220192]
  2. Sci Rep. 2019 Jun 12;9(1):8580 [PMID: 31189947]
  3. Cancer Manag Res. 2014 Jul 02;6:291-300 [PMID: 25061338]
  4. BMC Med. 2019 Jul 29;17(1):150 [PMID: 31352904]
  5. Stat Methods Med Res. 2013 Jun;22(3):243-60 [PMID: 21632696]
  6. Br J Surg. 2003 Jun;90(6):711-5 [PMID: 12808619]
  7. JAMA. 2018 May 22;319(20):2095-2103 [PMID: 29800179]
  8. Clin Colorectal Cancer. 2009 Jul;8(3):141-5 [PMID: 19632928]
  9. Int J Cancer. 2015 Nov 1;137(9):2133-8 [PMID: 25912489]
  10. Am J Epidemiol. 2015 Jun 1;181(11):832-45 [PMID: 25888582]
  11. Cancer Res. 2017 Jul 15;77(14):3814-3822 [PMID: 28512242]
  12. J Clin Oncol. 2010 Jan 10;28(2):264-71 [PMID: 19949014]
  13. Am J Gastroenterol. 2011 Nov;106(11):1911-21; quiz 1922 [PMID: 21912438]
  14. Eur J Cancer. 2014 Jul;50(10):1731-1739 [PMID: 24814358]
  15. Nat Med. 2015 Nov;21(11):1350-6 [PMID: 26457759]
  16. Dis Colon Rectum. 2009 Dec;52(12):1982-91 [PMID: 19959975]
  17. J Gastrointest Oncol. 2015 Dec;6(6):605-12 [PMID: 26697191]
  18. Surg Clin North Am. 2002 Oct;82(5):1091-108 [PMID: 12507211]
  19. PLoS One. 2017 Oct 31;12(10):e0186547 [PMID: 29088245]
  20. Biometrics. 2000 Mar;56(1):227-36 [PMID: 10783800]
  21. Surgery. 2018 Jun;163(6):1238-1244 [PMID: 29455841]
  22. JAMA. 2014 Jan 15;311(3):263-70 [PMID: 24430319]
  23. PLoS One. 2013 Jul 05;8(7):e68077 [PMID: 23861851]
  24. Asian Pac J Cancer Prev. 2013;14(2):1083-7 [PMID: 23621191]
  25. Comput Methods Programs Biomed. 2012 Dec;108(3):1255-60 [PMID: 23017250]
  26. Asian Pac J Cancer Prev. 2016;17(3):1193-6 [PMID: 27039747]
  27. Cell Tissue Bank. 2017 Sep;18(3):425-431 [PMID: 28258397]
  28. J Clin Oncol. 2013 Jun 1;31(16):2047-54 [PMID: 23630217]
  29. Biostatistics. 2007 Jul;8(3):576-94 [PMID: 17021277]
  30. Int J Colorectal Dis. 2014 Sep;29(9):1081-9 [PMID: 24980687]
  31. N Engl J Med. 2016 Aug 25;375(8):794-8 [PMID: 27557308]
  32. Cancer. 2010 Oct 15;116(20):4849-56 [PMID: 20578180]
  33. Ann Oncol. 2005 May;16(5):767-72 [PMID: 15817594]
  34. Clin Cancer Res. 2012 Jul 15;18(14):3731-6 [PMID: 22675175]
  35. Cir Esp (Engl Ed). 2018 Feb;96(2):96-101 [PMID: 29397879]
  36. Ann Surg. 2011 Aug;254(2):289-93 [PMID: 21709543]
  37. J Clin Pathol. 1981 May;34(5):509-13 [PMID: 7251893]
  38. Lancet Oncol. 2020 Sep;21(9):1124-1125 [PMID: 32717181]
  39. J Am Geriatr Soc. 2011 Apr;59(4):694-8 [PMID: 21438864]
  40. Ann Oncol. 2017 May 1;28(5):1023-1031 [PMID: 28453697]
  41. Eur J Cancer. 2009 Apr;45(6):1017-27 [PMID: 19109009]

MeSH Term

Colonic Neoplasms
Colorectal Neoplasms
Humans
Neoplasm Recurrence, Local
Neoplasm Staging
Prognosis
Prospective Studies
Retrospective Studies

Word Cloud

Created with Highcharts 10.0.0patientscurestageprobabilitypoordataCRCdiseasegradecancercohortwithoutrecurrencefactorsI-IIImulticenterstudysurvivalratePatients95%respectivelymortalityearlysimilartrendIIItumorpostoperativecomplicationssarcopeniaR1resectionsstandardtherapyBACKGROUND:Colorectalthirdcommontypeworldcharacterizesurvived5yearsidentifypredictingMETHODS:analyzedunderwentcurativeintentsurgery20072012includedlargeNetherlandsCuredefined5-yearSurvivalretrievednationalregistryRESULTS:Analysis754revealed65%n=490T1-N0-tumorhighest94%90%T4-tumorN2-tumorlowest62%50%peakolderfollow-upsuggestsexcessexplanationobservedshowdecreaseCSSdeathstimeCONCLUSION:studiedranged50EventhoughwillcuredinsufficientprognostichighT-N-stagedifferentiationActualresectionprimarycolorectalcancer:resultsprospective

Similar Articles

Cited By